Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25283 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL10404578 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL2133320 | 0.96 | KDM4E (0.52) | KDM4EALDH1A1HPGDMAPTTHRB | |
| Silver SCHEMBL191053 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL4966622 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| Lithium Ion SCHEMBL1457619 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL4393614 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| Potassium Ion SCHEMBL5250865 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL20484784 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB | |
| SCHEMBL11433030 | 0.96 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1733 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3457848-B1 | AGROCHEMICAL COMBINATION | CROP INTELLECT LTD (GB) | 2024-08-07 | — | — | EP | claimed |
| US-20240041935-A1 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-02-08 | — | — | US | claimed |
| CN-108329205-B | Preparation method of bis (2-acetoxybenzoic acid) calcium urea compound | 山东新华制药股份有限公司 | 2021-04-02 | — | — | CN | claimed |
| US-10912295-B2 | Agrochemical combination | CROP INTELLECT LTD. (GB) | 2021-02-09 | — | — | US | claimed |
| EP-2822532-B1 | AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE | COVESTRO DEUTSCHLAND AG (DE) | 2018-09-19 | — | — | EP | claimed |
| CN-106729644-A | A kind of gentle multiple-effect ectylotic and preparation method thereof | 郑州兰茜生物工程有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-106420491-A | Multifunctional skin care product with effects of whitening skin, removing freckles, preserving moisture and removing wrinkle and preparation method of multifunctional skin care product | 郑州兰茜生物工程有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106389139-A | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | 河南工业大学 | 2017-02-15 | — | — | CN | claimed |
| US-20150080352-A1 | AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE | BAYER MATERIALSCIENCE LLC (US) | 2015-03-19 | — | — | US | claimed |
| EP-2822532-A2 | AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE | Bayer Intellectual Property GmbH (DE) | 2015-01-14 | — | — | EP | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| WO-1998020864-A2 | USE OF SELECTED NON-STEROIDAL ANTIINFLAMMATORY COMPOUNDS FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITA' DEGLI STUDI DI BRESCIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE (IT) | 1998-05-22 | — | — | WO | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0024690-B1 | ANALGESIC MIXTURE OF NALBUPHINE AND ACETYLSALICYLIC ACID, DERIVATIVE OR SALT THEREOF | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-07-20 | — | — | EP | claimed |
| US-4282215-A | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-08-04 | — | — | US | claimed |
| EP-0024690-A1 | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-03-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080352-A1 | AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE | UROD, CUTA, PUF60 | KDM4E 4264/4885ALDH1A1 108/4885HPGD 75/4885 |
| US-10912295-B2 | Agrochemical combination | PLD1, ITPA, PLD2 | KDM4E 2368/4885ALDH1A1 705/4885HPGD 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.